Granted Patent B2

US 12,377,245 · App. 17/376,115 · Granted Aug 5, 2025

Inventors: David Benjamin Jaroch (Arvada, CO); James E. Chomas (Denver, CO)

Assignee: TriSalus Life Sciences, Inc.

A61M25/0029A61L29/041A61L29/06A61L29/08A61L29/085A61L29/145A61L29/16A61M25/04A61M25/10A61F2/013A61L2300/426A61L2300/608A61L2400/10A61L2420/02A61L2420/08A61M2025/0004A61M2025/0042A61M2025/0047A61M2025/105A61M2025/1052A61M2202/0007

Abstract

Claims (23)

1. A method of delivering a therapeutic agent through a target vessel in communication with a tumor, the method comprising:

a) inserting a delivery device into the target vessel, the delivery device comprising a flexible catheter having a proximal end and a distal end, an expandable fluid pressure modulating structure fixed adjacent the distal end of the flexible catheter, an agent delivery lumen extending through the flexible catheter from the proximal end of the flexible catheter to the distal end of the flexible catheter and opening to an orifice at a distal tip of the flexible catheter, wherein the agent delivery lumen is coated or structured to be hydrophobic and is coated or structured to reduce wall shear stress during infusion;

b) deploying the expandable fluid pressure modulating structure in the target vessel to generate turbulent flow within the target vessel distal to the expandable fluid pressure modulating structure; and

c) infusing the therapeutic agent through the agent delivery lumen, out of the orifice of the flexible catheter, and into the turbulent flow generated within the target vessel, while the expandable fluid modulating structure blocks retrograde flow of the therapeutic agent proximal of the expandable fluid pressure modulating structure.

2. The method of claim 1 ,

wherein the therapeutic agent comprises an immunotherapy agent.

3. The method of claim 2 ,

wherein the agent delivery lumen is coated and structured to be hydrophobic.

4. The method of claim 2 ,

wherein the therapeutic agent comprises immunotherapy cells.

5. The method of claim 2 ,

wherein the therapeutic agent comprises an immunomodulator.

6. The method of claim 5 ,

wherein the immunomodulator is a cytosine phosphate-guanosine oligodeoxynucleotide.

7. The method of claim 1 ,

wherein the expandable fluid pressure modulating structure is a microvalve configured to dynamically move between open and closed configurations responsive to fluid pressure conditions within the target vessel.

8. The method of claim 1 ,

wherein the coating of the agent delivery lumen is selected from the group consisting of silicones and silicone oils, polypropylene, polyethylene and fluoropolymers.

9. The method of claim 1 ,

wherein the delivery device further comprises an outer catheter, the flexible catheter extending through the outer catheter, and the outer catheter being longitudinally displaceable relative to the flexible catheter; and

wherein the expandable fluid pressure modulating structure is deployed by longitudinally displacing the outer catheter relative to the flexible catheter.

10. The method of claim 1 , wherein the agent delivery lumen comprises a structure comprising at least one feature selected from the group consisting of micro or nano scale ridges, or pillars.

11. The method of claim 1 , wherein the agent delivery lumen is coated or structured to prevent engaging with the therapeutic agent during infusion.

Assignments (3)

Continuity (4)

References Cited (400)